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ABSTRACT
Migraine is a common genetically linked neurovascular disorder. Approximately ~12% of the Caucasian 
population are affected including 18% of adult women and 6% of adult men (1, 2). A notable female bias is 
observed in migraine prevalence studies with females affected ~3 times more than males and is credited to 
differences in hormone levels arising from reproductive achievements. Migraine is extremely debilitating 
ZLWKZLGHUDQJLQJVRFLRHFRQRPLFLPSDFWVLJQL¿FDQWO\DIIHFWLQJSHRSOH¶VKHDOWKDQGTXDOLW\RIOLIH$QXPEHU
of neurotransmitter systems have been implicated in migraine, the most studied include the serotonergic and 
dopaminergic systems. Extensive genetic research has been carried out to identify genetic variants that may 
alter the activity of a number of genes involved in synthesis and transport of neurotransmitters of these sys-
tems. The biology of the Glutamatergic system in migraine is the least studied however there is mounting evi-
dence that its constituents could contribute to migraine. The discovery of antagonists that selectively block 
glutamate receptors has enabled studies on the physiologic role of glutamate, on one hand, and opened new 
perspectives pertaining to the potential therapeutic applications of glutamate receptor antagonists in diverse 
neurologic diseases. In this brief review, we discuss the biology of the Glutamatergic system in migraine 
RXWOLQLQJUHFHQW¿QGLQJVWKDWVXSSRUWDUROHIRUDOWHUHG*OXWDPDWHUJLFQHXURWUDQVPLVVLRQIURPELRFKHPLFDO
and genetic studies in the manifestation of migraine and the implications of this on migraine treatment. (Int 
J Biomed Sci 2012; 9 (1): 1-8)
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INTRODUCTION
Migraine is a complex debilitating neurovascular dis-
order, characterized by recurrent attacks of headache that 
differ in intensity, frequency and duration. The headache 
is often associated with an assortment of symptoms which 
can include nausea, emesis, photophobia, phonophobia, 
and occasionally, visual sensory disturbances. Migraine is 
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estimated to affect approximately 12% of the Caucasian 
population (3) and shows a marked female preponderance 
a0LJUDLQH LPSDUWVVLJQL¿FDQWPHQWDOSK\VLFDODQG
social health implications to sufferers and their families. 
Most migraine sufferers probably possess a number of 
genes that together contribute to susceptibility. Thus far 
genetic linkage and association studies have implicated 
a number of susceptibility genes and causative mutations 
WKDWDUHRIVLJQL¿FDQWFOLQLFDOUHOHYDQFHLQPLJUDLQH+RZ-
ever not all migraine genes have been uncovered and fur-
WKHUUHVHDUFKLVQHFHVVDU\WRGHWHUPLQHWKHGH¿QLWLYHPR-
lecular genetics of migraine. Numerous theories regarding 
the causes and underlying mechanisms that result in mi-
graine symptoms have also been proposed. 
The pathophysiology of this disorder implicates both 
neurological and vascular mechanisms. Current research 
suggests that the trigeminovascular system plays a sig-
QL¿FDQW UROH LQPLJUDLQH GXH WR LWVFULWLFDO LQWHUDF-
tion with the meningeal vasculature and because various 
neurotransmitters, peptides, receptors and transporters are 
located in this system. The neurotransmitters implicated 
in migraine pathogenesis include: serotonin, dopamine 
and glutamate. An alteration in the balance of any of these 
neurological systems may lead to a higher susceptibility 
to migraine. Currently serotonin and dopamine remain 
the most studied neurotransmitter circuits in case-control 
association studies investigating polymorphisms in recep-
tors, transporters, and enzymes of these systems (7, 8). 
Migraine has a strong inherited component, and a large 
genetic study (9) suggests the involvement of glutamate 
pathways in migraine pathogenesis. Glutamate is impli-
cated in elements of the pathophysiology of the disorder, 
including trigeminovascular activation, central sensitiza-
tion and cortical spreading depression. Biochemical and 
pharmacological studies also support involvement of glu-
tamate in migraine.
GLUTAMATERGIC BIOLOGY
7KHSLRQHHULQJZRUNRI+D\DVKL LQ HVWDEOLVKHG
WKHSK\VLRORJLFDO VLJQL¿FDQFHRIJOXWDPDWHDV DQH[FLW-
DWRU\QHXURWUDQVPLWWHU +D\DVKLGHPRQVWUDWHGJOX-
tamate’s role as a neurotransmitter in the CNS in ex-
periments in dogs, monkeys and men, where injection of 
monosodium glutamate into the grey matter of the cortex 
was found to produce clonic convulsions (10). 
Glutamate is a nonessential amino acid that does not 
cross the blood-brain barrier but must be synthesized 
inside neurons from local precursors (11). Glutamate is 
found in neurons of structures related to migraine patho-
physiology, including the trigeminal ganglion, trigemino-
cervical complex and the thalamus (12). Glutamate has a 
number of metabolic fates in brain, including oxidation via 
the TCA cycle for energy, incorporation into proteins, and 
IRUPDWLRQRIJOXWDPLQHȖDPLQREXW\ULFDFLG*$%$DQG
glutathione (13). The brain contains large amounts of glu-
tamate the majority of which is stored intracellularly (13). 
Glutamate is cycled continuously between neurons and 
glial cells in what is known as the glutamate-glutamine 
cycle under normal conditions (13). There are a number 
of enzymes involved in this cycling as outlined in Table 1 
that are important for the metabolism of Glutamate and are 
subject to regulation. 
The neuronal/glial cell interface where glutamate cy-
cling occurs contains glutamate receptors, which are re-
sponsible for signal input; plasma glutamate transporters, 
which are responsible for signal termination and vesicular 
glutamate transporters for signal output through exocytic 
release . These are the biological constituents of the 
Glutamatergic system. The Glutamatergic system of the 
brain is one of the two major amino acid systems, GABA 
being the other. The glutamate system is a fast-signalling 
system that is very important for information processing 
in neuronal networks of the neocortex and hippocampus. 
GLUTAMATE RECEPTORS
Glutamate is the most abundant excitatory neurotrans-
mitter in the brain; it is critical to the communication of 
nerve cells with one another in practically every circuit 
in the nervous system. Glutamate communicates in this 
circuit via two main subtypes of membrane receptors, 
Table 1. Enzymes involved in glutamate cycling
Enzymes 
3'+S\UXYDWHGHK\GURJHQDVH
PAG, phosphate activated glutaminase
mME, mitochondrial malic enzyme
GAD, glutamic acid decarboxylase
GS, glutamine synthetase
PC, pyruvate carboxylase
cME, cytosolic malic enzyme
AAT, aspartate aminotransferase
*'+JOXWDPDWHGHK\GURJHQDVH
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ionotropic and metabotropic. The family of ionotropic re-
ceptors is divided into three groups, referred to as N-meth-
\O'DVSDUWDWH10'$UHFHSWRUVĮDPLQRK\GUR[\
PHWK\OLVR[D]ROHSURSLRQDWH$03$DQGNDLQDWH.$
receptors on the basis of DNA sequence similarity and 
their activation by different pharmacologic agonists (Ta-
EOH7KHIDPLO\RIPHWDERWURSLFUHFHSWRUVP*OX5V
consists of at least eight receptor types also divided into 
three groups (Table 3). 
The difference between ionotropic and metabotropic 
receptors is that ionotropic receptors are ligand-gated 
ion channels, while the metabotropic receptors (Table 3) 
P*OX5VDUH*SURWHLQFRXSOHGUHFHSWRUVDQGWKHLUDFWL-
vation is coupled to an intracellular biochemical cascade 
OHDGLQJ WRPRGXODWLRQ RI VHFRQGPHVVHQJHUV They 
are strategically situated on several cell types converging 
on the glutamate synapse: pre and post-synaptic neurons, 
astrocytes (a type of glial cell), and nearby inhibitory neu-
URQVWKDWXVH*$%$Glutamatergic receptors have 
been extensively studied in neurologic diseases. 
An interesting genetic mechanism pertinent to a dis-
FXVVLRQRI*5,$UHFHSWRUVLVWKDWWKH*OX5VXEXQLWXQ-
GHUJRHV51$HGLWLQJDWDVSHFL¿FSRLQWNQRZQWRDIIHFW
the Ca2+ SHUPHDELOLW\ RI WKH FKDQQHO  7KH SRVLWLRQ
that regulates the Ca2+ SHUPHDELOLW\ LV WKH45 VLWH DQG
WKLVLVHGLWHGE\WKH$'$5HQ]\PH7KLVJHQHSHUIRUPV
WKH51$HGLWLQJIXQFWLRQQHFHVVDU\IRUWKHPDWXUDWLRQRI
glutamate and serotonin receptor transcripts and therefore 
SOD\VDQLPSRUWDQWUROHLQWKHUHJXODWLRQDQG¿QHWXQLQJ
RI*OXWDPDWHUJLFQHXURWUDQVPLVVLRQ$'$5HQ]\PHV
are generated in humans by three independent genes 
$'$5 ORFDWHG RQ FKURPRVRPHV   DQG  
7KHUH LV VRPHHYLGHQFHRI LQYROYHPHQWRI DQRWKHU51$
HGLWLQJJHQH$'$5%IURPDSHGLJUHHEDVHG*:$6LQ
WKH1RUIRON,VODQGSRSXODWLRQ
51$ HGLWLQJ LV D SK\VLRORJLFDOO\ LPSRUWDQW SURFHVV
that affects several features of the receptors, including ki-
netics, subunit assembly and cell-surface expression and 
if editing is prevented the channels become permeable to 
Ca2+FDXVLQJQHXURQDOFHOOGHDWK Other neuronal 
JHQHVDIIHFWHGE\$WR,51$HGLWLQJ LQFOXGH WKHJOXWD-
PDWHUHFHSWRUVXEXQLWV*OX5DQGZKHUH51$
editing regulates gating and kinetic properties of the ion 
FKDQQHOV WKH +72C serotonin receptor subtype where 
editing is known to regulate G-protein coupling functions 
RIWKHUHFHSWRUDQGWKH.9SRWDVVLXPFKDQQHOZKHUH
HGLWLQJUHJXODWHVFKDQQHOLQDFWLYDWLRQ
51$HGLWLQJJHQHVKDYHEHHQVXJJHVWHGDVFDQGLGDWH
genes for complex neurological disorders such as epilep-
sy, depression and schizophrenia and amyotrophic lateral 
sclerosis (ALS). 7KH UROH RI DGHQRVLQH GHDPLQDVH51$
editing of glutamate and serotonin receptor transcripts is 
IXUWKHU H[HPSOL¿HG E\ WKH GLVRUGHU DP\RWURSKLF ODWHUDO
VFOHURVLV $/6 0,0  ,Q DP\RWURSKLF ODWHUDO
VFOHURVLV $/6 HGLWLQJ RI P51$ HQFRGLQJ WKH *OX5
subunit of glutamate AMPA receptors in spinal motor 
Table 2. ,RQRWURSLFJOXWDPDWHUHFHSWRUV
Receptor Type Gene Chromosome (Human)
AMPA *5,$ T
AMPA *5,$ T
AMPA *5,$ ;T
AMPA *5,$ 11q22-23
.DLQDWH *5,. 21q21.1-22.1
.DLQDWH *5,. TT
.DLQDWH *5,. SS
.DLQDWH *5,. 11q22.3
.DLQDWH *5,. T
NMDA *5,1 T
NMDA *5,1$ S
NMDA *5,1% 12p12
NMDA *5,1& TT
NMDA *5,1' 19q13.1qter
NMDA *5,1$ 9q31.1
NMDA *5,1% 19p13.3
Orphan *5,' -
Orphan *5,' T
Table 3. Metabotropic glutamate receptors
Receptor Type Gene Chromosome (Human)
P*OX51 *50 T
P*OX5 *50 T
P*OX52 *50 3p21.2
P*OX53 *50 7q21.1-q21.2
P*OX5 *50 S
P*OX5 *50 T
P*OX57 *50 SS
P*OX58 *50 7q31.3-q32.1
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neurons is defective and interferes with normal function-
LQJ RI WKH JOXWDPDWH UHFHSWRUV .QRFNRXWPLFH LQ 51$
editing genes are lethal implying that this mechanism is 
essential for survival and dysregulation could potentially 
DIIHFW*OXWDPDWHUJLFIXQFWLRQ*HQHVLQYROYHGLQ51$HG-
iting are candidate genes to investigate due to the impact 
that this mechanism has on the Glutamatergic system.
GLUTAMATE RECEPTOR STRUCTURE
X-ray crystal structures have produced 3D images that 
have helped understand the structural basis of glutamate 
receptors revealing which domains are involved in bind-
ing to agonists and antagonists and to study the effect of 
mutations on protein conformation to understand how 
this relates to neuronal function in neurological disease. 
So far a number of structures have been described for a 
membrane-spanning tetrameric glutamate receptor as 
well as in complex with various agonists, antagonists, and 
modulators (21-27). These experiments have been possible 
due to advances in molecular modelling and structural bi-
ology techniques. These data, along with functional and 
ELRFKHPLFDO H[SHULPHQWVKDYHEHJXQ WRGH¿QH WKH UHOD-
tionship between receptor structure and function and have 
contributed to understanding the neurotransmitter binding 
mechanisms at the synapse. 
GLUTAMATE TRANSPORT
Glutamate concentrations in the extracellular space 
under normal conditions are kept low and tightly con-
trolled by EAAT transporters present in both nerve end-
ings and surrounding glial cells. Perturbations to this 
regulatory system can have deleterious effects such as 
excess release of glutamate, which can induce hyperex-
citability in post-synaptic neurons to the point of excito-
WR[LFLW\DQGFHOOGHDWKThe transport process is con-
sidered to be primarily responsible for the termination of 
neurotransmitter action of glutamate and the prevention 
of neuronal damage from excessive activation of gluta-
mate receptors (28).
There are two transport systems: the plasma GluTs, 
that are responsible for signal termination; and the ve-
sicular GluTs for signal output through exocytic release. 
)LYHGLIIHUHQWµKLJKDI¿QLW\¶JOXWDPDWHH[FLWDWRU\DPLQR
DFLGWUDQVSRUWHUVKDYHEHHQLGHQWL¿HGE\FORQLQJLQFOXG-
ing Excitatory Amino Acid Transporters located in the 
SODVPDPHPEUDQH($$7($$7($$7($$7DQG
($$7 7KH YHVLFXODU*OX7V DUH FUXFLDO IRU WKH VWRUDJH
RI*OXLQV\QDSWLFYHVLFOHVWKUHHLVRIRUPVH[LVW9*/87
9*/879*/87*HQHWLFPXWDWLRQVLQUHFHSWRUV
transporters and enzymes involved in glutamate metabo-
lism could contribute to derailed function of the Gluta-
matergic system and these are key candidates for future 
genetic studies.  
GLUTAMATE TOXICITY
Observations by Lucas and Newhouse LQ  
described the toxic properties of glutamate by injecting 
monosodium glutamate into the neurons of the retina 
from newborn mice. The term “glutamate excitotoxicity” 
was introduced by Olney (31) to describe the toxic action 
of glutamate which caused neuronal cell death. Excito-
toxicity is the pathological process by which nerve cells 
are damaged and killed by excessive stimulation of neu-
rotransmitters such as glutamate and similar substances 
and is considered a normal physiological response to CNS 
insult (32). 
Excitotoxicity may be involved in stroke, traumatic 
brain injury and neurodegenerative diseases of the cen-
tral nervous system (CNS) such as Multiple sclerosis, Al-
zheimer’s disease, Amyotrophic lateral sclerosis (ALS), 
)LEURP\DOJLD3DUNLQVRQ¶VGLVHDVHDQG+XQWLQJWRQ¶VGLV-
ease. The mechanism of this excitotoxicity is thought to 
be due to the entry of high levels of Ca2+ ions into the cell 
from over stimulation with glutamate (33). Ca2+LQÀX[LQWR
cells activates a number of enzymes, including phospho-
lipases, endonucleases, and proteases such as calpain that 
go on to damage cell structures such as components of the 
F\WRVNHOHWRQPHPEUDQHDQG'1$7KLVLVWKRXJKWWR
be the mechanism that leads to neuronal cell death. Exces-
VLYHDFWLYDWLRQRI*OX5VGXULQJVWUHVVWRWKHEUDLQVXFKDV
ischemia, head trauma, and epileptic seizures leads to the 
death of central neurons. 
MIGRAINE MOLECULAR GENETICS
Our understanding of ‘migraine genetics’ is an evolv-
ing subject due to its relative novelty in this disease sys-
tem. There have been some successes such as the recent 
LGHQWL¿FDWLRQ RI D IXQFWLRQDO PXWDWLRQ LQ WKH .&1.
JHQH 7KH.&1. JHQH HQFRGHV75(6. D SRWDVVLXP
FKDQQHOWKDW LVSDUWRIWKHVXEIDPLO\.PHPEHU.3
channels, which are expressed throughout the central ner-
vous system, including the trigeminal ganglion neurons 
()$QXPEHURIPXWDWLRQVLQWKLVJHQHZHUHLGHQWL¿HG
using a candidate gene approach and functional analy-
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sis, in a large cohort of both case-control individuals and 
multi-generational families by directly Sanger sequencing 
the DNA of a panel of 110 unrelated migraine probands 
7KHPRVWQRWDEOHYDULDQWLGHQWL¿HGZDVDIUDPHVKLIW
PXWDWLRQ):IV;ZKLFKVHJUHJDWHGSHUIHFWO\LQD
IDPLO\DIIHFWHGZLWKW\SLFDO0$7KH75(6.LVLQYROYHG
in pain pathways and regulates neuronal excitability and is 
DQH[FLWLQJGLVFRYHU\EHFDXVHLWLVWKH¿UVWJHQHWLFPXWD-
tion to be linked to common migraine (37).
The most established molecular knowledge of mi-
graine comes from mutations in the three genes for fa-
PLOLDO KHPLSOHJLF PLJUDLQH )+0 ± &$&1$$ $7-
3$DQG6&1$)DPLOLDOKHPLSOHJLFPLJUDLQH
)+0 LV D UDUH IRUP RI PLJUDLQH GLVWLQJXLVKHG IURP
classical migraine, by a prolonged aura and a more genet-
ically determined component. Transcription of the three 
causal genes results in protein products that assemble to 
make heteromeric ion channels in the plasma membranes 
of cells. 0XWDWLRQVLQ)+0JHQHVDUHWKRXJKWWRLQFUHDVH
neuronal excitability and reduce the threshold for corti-
cal spreading depression. Disorders attributed to muta-
WLRQVLQLRQFKDQQHOJHQHVKDYHEHHQFODVVL¿HGDVµFKDQ-
QHORSDWKLHV¶ 0RUH WKDQ  GLIIHUHQW FKDQQHORSDWKLHV
KDYH EHHQ LGHQWL¿HG DIIHFWLQJ DOO HOHFWULFDOO\ H[FLWDEOH
tissues: brain, peripheral nerve, skeletal muscle, smooth 
PXVFOH DQG KHDUW   )+0 KDV EHHQ LQFOXGHG LQ
this list following the discovery that two of its causative 
genes encode voltage-gated ion channels and as a result 
has strengthened the idea of migraine as a disorder of 
‘neuronal excitability’. 
,RQFKDQQHOJHQHVSOD\DFULWLFDOUROHLQQRUPDOIXQF-
tioning of the central nervous system where they control 
important biological functions including the release of 
QHXURWUDQVPLWWHUVKRUPRQHVDQGPXVFOHFRQWUDFWLRQ
,RQFKDQQHOVDUHPDFURPROHFXODUSURWHLQFRPSOH[HV WKDW
span the membrane lipid bilayer and facilitate the move-
ment of ions across this hydrophobic barrier that separates 
the cytoplasm from the extracellular space or from intra-
FHOOXODU RUJDQHOOHV  ,RQÀX[ WKURXJK FKDQQHOV LV WKH
source of the electric current to regulate the membrane 
potential and thus is the fundamental basis for cellular 
electrical excitability. Minute alterations in the amino acid 
sequence or expression of these ion channels from genetic 
mutations can result in changes affecting the biophysical 
properties of the channel such as permeation and gating. 
7KLVLVRIVLJQL¿FDQWFRQVHTXHQFHWRQHXURORJLFDOUHWLQDO
cardiac, and muscular tissues that rely on fast signal trans-
mission and gross pathological changes can lead to serious 
FKURQLFGLVRUGHUV
GLUTAMATE GENETIC STUDIES
Genetic association studies have mostly investigated 
variants in serotonin and dopamine receptor genes. Fewer 
studies have been done in relation to the genetics of the Glu-
WDPDWHUJLFV\VWHPLQPLJUDLQH7KH¿UVWJHQHWLFHYLGHQFH
of a link between migraine and glutamate was provided by 
Formicola et al., 2010 who found a positive association in 
613VLQWKH$03$UHFHSWRUV*5,$DQG*5,$LQDQ
,WDOLDQSRSXODWLRQ7KHLRQRWURSLF$03$*5,$UH-
FHSWRUVDUHFRPSULVHGRIVXEXQLWVFRGHGE\WKHJOXWDPDWH
UHFHSWRUWRJHQHVDWFKURPRVRPDOORFLTT;T
DQGTUHVSHFWLYHO\7KH$03$UHFHSWRUSURWHLQV
are products of separate genes that arrange to form ligand-
gated ion channels in the plasma membrane permeable to 
Na+.+ and Ca2+ 7KH IRXU GRPDLQV DUH DUUDQJHG LQ
a tetrameric structure to form a transmembrane aqueous 
SRUH7ZR613VLQ*5,$TUV02DO-
OHOLF3 UV0$DOOHOLF3 DQG613
LQ*5,$UV0$)HPDOHVDOOHOLF3 VKRZHG
D SRVLWLYH DVVRFLDWLRQZLWKPLJUDLQH  7KH UHPDLQLQJ
VXEIDPLOLHV RI NDLQDWH .$ DQG 1PHWK\O'DVSDUWDWH
(NMDA) and metabotropic receptors are yet to be investi-
JDWHGLQPLJUDLQHDVVRFLDWLRQVWXGLHV,WLVQRWHZRUWK\WKDW
genes of the Glutamatergic system have also been investi-
gated in association studies of other disorders like schizo-
phrenia given their neuronal role.  
The role of glutamate in migraine pathology has gained 
momentum with the recent discovery of a plausible genetic 
risk variant implicated in a large-scale genome wide asso-
FLDWLRQVWXG\RIPLJUDLQH7KH*:$6SXEOLVKHGE\$Q-
tilla, et al., 2010 found the genetic risk variant to be locat-
HGEHWZHHQWKHJHQHV07'+DQG3*&3ERWKRIZKLFKDUH
in pathways thought to regulate glutamate accumulation in 
Table 4. Glutamate transporters
Transporter Type Gene Chromosome (Human)
EAAT1 SLC1A3 S
EAAT2 SLC1A2 11p13
EAAT3 SLC1A1 S
($$7 6/&$ 19p13.12
($$7 SLC1A7 1p32.3
9*/87 SCL17A7 9q13.33
9*/87 6&/$ S
9*/87 SCL17A8 12q23.1
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WKHV\QDSWLFFOHIW7KHYDULDQWDIIHFWV07'+JHQHH[SUHV-
sion and thereby indirectly regulates the expression of the 
glutamate transporter gene EAAT2, encoding a major glu-
tamate transporter in the brain. The effect of this marker 
was consistently stronger in the migraine with aura only 
JURXSV WKDQ RWKHUPLJUDLQH VXEJURXSV ZLWK 3 [-9 
and odds ratios ranging between 1.21 and 1.33. Due to the 
role of these two genes in glutamate homeostasis, it seems 
that complementary pathways such as the glutamate sys-
tem could fasten mendelian channelopathies with patho-
genesis of common forms of migraine (9).
,QDGGLWLRQWRJOXWDPDWHUHFHSWRUVJOXWDPDWHWUDQVSRUW-
ers can contribute to neurologic dysfunction and could be 
useful molecular targets for treatment. EAAT transporters 
play a key role in the regulation of extracellular glutamate 
levels in the central nervous system where they protect 
neurons from excitotoxic damage. A number of studies 
have implicated EAATs in the pathophysiology of stroke, 
HSLOHSV\DP\RWURSKLFODWHUDOVFOHURVLV$/6+XQWLQJWRQ
'LVHDVH+,9DVVRFLDWHGGHPHQWLDPDOLJQDQWJOLRPDDQG
RWKHUQHXURORJLFGLVRUGHUV-HQet al.H[DPLQHG
a de novo mutation in the transporter EAAT1, in a patient 
with episodes of ataxia, migraine, hemiplegia and seizures 
 7KH DXWKRUV FRQFOXGHG WKDW WKH PLVVHQVH PXWDWLRQ
35FRQWULEXWHGWRQHXURQDOK\SHUH[FLWDELOLW\WKURXJK
decreased transporter function resulting in the hemiplegia 
and other neurological symptoms. 
Another study of the EAAT1JHQHE\GH9ULHVHWDO
2009 LQ SDWLHQWVZLWK (SLVRGLF$WD[LD ($ LGHQWL¿HG D
QRYHOSDWKRJHQLFPXWDWLRQ&6LQRQHSDWLHQW7KHPX-
tated EAAT1 protein showed severely reduced uptake of 
glutamate  The severity of EA symptoms appears to 
be correlated with the extent of glutamate transporter dys-
IXQFWLRQ7KHV\QGURPHZDVGHVLJQDWHG($DQGVKDUHV
overlapping clinical features with EA2, which is caused by 
PXWDWLRQVLQ&$&1$$WKH)+0ORFXV
An association study by Shin et al., 2011 evaluated the 
contribution of polymorphisms in the EAAT2 transporter 
and found no direct association between this genetic fac-
WRUDQGPLJUDLQH 7KH($$7 WUDQVSRUWHUKDVEHHQ
investigated in association with a number of other dis-
orders given it is responsible for up to 90% of all gluta-
PDWHWUDQVSRUWLQDGXOWWLVVXH$VWXG\E\0DOOR-
las and colleagues has found a novel and highly prevalent 
polymorphism in the promoter of the EAAT2 glutamate 
transporter gene. This polymorphism was associated with 
higher and maintained plasma glutamate concentrations as 
well as with higher frequency of neurological deterioration 
LQSDWLHQWVZLWKDFXWHKHPLVSKHULFVWURNH ,QFRQFOXVLRQ
this study has revealed a novel functional polymorphism 
in the EAAT2 promoter region and a pattern of regulation 
that decreases promoter activity. 
Alterations in the function or expression of compo-
nents of this system may be involved in migraine suscep-
tibility. Further research into the Glutamatergic system is 
necessary to ascertain its role in migraine aetiology. 
GLUTAMATERGIC SYSTEM AND CLINICAL 
IMPLICATIONS
Pharmacological compounds capable of modulating 
glutamate receptors have helped untangle the functional 
role of glutamate receptor family members and present 
promising targets for the treatment of migraine. Consider-
able scope however remains for the development of novel 
ligands that will encompass the family of glutamate recep-
tors. Currently the most promising compounds reported in 
the literature include: topiramate, ketamine and meman-
tine. Several types of drugs, like generic beta blockers, 
calcium channel blockers, tricyclic antidepressants and 
anti-epileptic drugs are given to prevent migraines, these 
are not always effective in all patients. Targeting the glu-
tamatergic system offers a novel approach to treatment in 
YLHZRIWKHOLPLWHGHI¿FDF\RIH[LVWLQJGUXJV 
Topiramate is a derivative of the naturally occurring 
monosaccharide D-fructose that was originally developed 
as an anticonvulsant and is recognized as an effective 
PHGLFDWLRQIRUPLJUDLQHSUHYHQWLRQ7RSLUDPDWHLVD
glutamate receptor antagonist within the trigeminotha-
lamic pathway. Topiramate has several actions which are 
relevant, including the blockade of Na+ and Ca2+ channels, 
enhancement of GABA activity, and blockade of iono-
WURSLFJOXWDPDWHUHFHSWRUV
$ IHZ RWKHU FRPSRXQGV 0HPDQWLQH .HWDPLQH DQG
$'; DUH GUXJV WKDW DFW RQ JOXWDPDWH VLJQDOOLQJ
WKURXJK10'$UHFHSWRUV0HPDQWLQHLVDPRG-
HUDWHDI¿QLW\QRQFRPSHWLWLYHDQWDJRQLVWDWJOXWDPDWHUJLF
1PHWK\O'DVSDUWDWH10'$UHFHSWRUV3UHFOLQLFDO
experiments and small scale studies in migraineurs with 
these drugs have been useful in demonstrating the role that 
NMDA receptors play in the “migraine circuit,” a positive 
feedback loop that generates the symptoms of a migraine 
attack.
CONCLUSION
Migraine is a disabling costly brain disorder, with hy-
pothesised involvement of neurotransmitters. The major 
MIGRAINE AND GLUTAMATERGIC BIOLOGY
www.ijbs.org    Int  J  Biomed  Sci    Vol. 9  No. 1    March  2013 7
excitatory neurotransmitter of the brain, glutamate and the 
receptors, upon which it acts, are intimately involved in 
trigeminovascular nociceptive processing. Given the im-
portance of the Glutamatergic system and its involvement 
in biological processes involved in the brain, genes of this 
system remain candidates for further investigation. The 
role of glutamate antagonists in the treatment of migraine 
is added evidence of a role for glutamate in migraine. 
Further research is required to elucidate the mechanism 
WKURXJKZKLFK*5,$JHQHVPD\ FRQWULEXWH WRPLJUDLQH
and to determine if other unknown mutations in compo-
nents of this system may be contributing to the migraine 
phenotype. 
Genetic characterization of migraine as a disorder is 
making steady progress with an increasing number of 
JHQRPLFVXVFHSWLELOLW\ ORFLQRZ LGHQWL¿HGThe data and 
ideas presented above have lent strong support implicating 
glutamate biology in migraine pathophysiology at the turn 
of the 21st century. The genetic studies are small and more 
data is needed to draw any solid conclusion about involve-
ment of Glutamatergic genes in migraine. Nonetheless the 
genetic evidence is growing with association, linkage and 
*:$6UHVXOWVEULQJLQJWROLJKWQHZYDULDQWVDQGJHQRPLF
regions. 
7KH LGHQWL¿FDWLRQRI WKHVHPLJUDLQHVSHFL¿F ORFLZLOO
FRQWULEXWHWRPRUHVSHFL¿FSKDUPDFRWKHUDSHXWLFVIRUWKH
patient. Genetic variation greatly affects patient response 
to treatment and further insight could lead to more indi-
vidualized treatments leading to better tolerability. 
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